Metformin Viatris

Metformin, the active ingredient in Metformin Viatris, is a biguanide presented as an oral tablet for oral use. It is employed to lower blood glucose in adults with type 2 diabetes mellitus and helps improve overall glycaemic control. Metformin works by decreasing hepatic glucose output and increasing peripheral insulin sensitivity, making it a cornerstone therapy in diabetes management.

GNH USA supplies Metformin Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformin Viatris is indicated for conditions within the diabetes and glucose‑regulation pathway.

- Type 2 diabetes mellitus: improves fasting and post‑prandial glucose levels and aids long‑term glycaemic control. - Prediabetes (impaired glucose tolerance): may be used to delay progression to overt diabetes. - Polycystic ovary syndrome (off‑label): can help reduce insulin resistance and improve ovulatory function.

Metformin may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, especially during treatment initiation. - Abdominal discomfort: cramping or bloating. - Metallic taste: transient alteration in taste perception.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening metabolic disturbance. - Severe hypoglycaemia: usually when combined with other glucose‑lowering agents. - Hepatic dysfunction: abnormal liver enzymes or hepatitis. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Pancreatitis: inflammation of the pancreas. - Anemia: unexplained reduction in red blood cells.

When prescribing Metformin Viatris, clinicians should consider several safety measures.

- Renal function monitoring: assess creatinine clearance before initiation and periodically thereafter. - Hepatic function assessment: evaluate liver enzymes to reduce risk of lactic acidosis. - Lactic acidosis risk: avoid use in patients with conditions predisposing to hypoxia or severe infection. - Concomitant hypoglycaemic agents: adjust doses of sulfonylureas or insulin to prevent low blood sugar. - Patient education: inform about symptoms of lactic acidosis and hypoglycaemia. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Metformin Viatris can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Iodinated contrast media: may precipitate acute renal failure and increase lactic acidosis risk. - Cimetidine: can raise metformin plasma concentrations. - Alcohol excess: enhances risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - NSAIDs: may impair renal function, affecting metformin clearance. - Loop diuretics: can reduce renal perfusion, necessitating dose review. - Beta‑blockers: may mask hypoglycaemia symptoms. - Corticosteroids: can increase blood glucose, requiring dose adjustments. - Thyroid hormones: may alter metabolic rate and glucose handling.